A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia

Journal of the American Geriatrics Society

Volumn 54, Issue 2, 2006, Pages 354-361

  Carson, Susan ^a   McDonagh, Marian S ^a   Peterson, Kim ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Atypical antipsychotics; Dementia; Systematic review

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DATA BASE; DEMENTIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION; INTERVENTION STUDY; MENTAL DISEASE; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PNEUMONIA; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; SUDDEN DEATH; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VALIDATION PROCESS; CONTROLLED CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33645086418     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.00566.x     Document Type: Review

References (29)

1. Diagnostic and Statistical Manual of Mental Disorders 4th Ed Washington, DC American Psychiatric Association 1994
2. Doody RS Stevens JC Beck C et al Practice parameter Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 2001 56 1154 1166
3. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances [on-line]. Available at Accessed May 24, 2005.
4. Food and Drug Administration. 2004 Safety Alert: Risperdal (risperidone) [on-line]. Available at Accessed October 4, 2005.
5. Dear Healthcare Professional. Health Canada Health Products and Food Branch [on-line]. Available at Accessed July 27, 2004.
6. Reisberg B Borenstein J Salob SP et al Behavioral symptoms in Alzheimer's disease Phenomenology and treatment J Clin Psychiatry 1987 48 Suppl 9 15
7. Cummings JL Mega M Gray K et al The Neuropsychiatric Inventory Comprehensive assessment of psychopathology in dementia Neurology 1994 44 2308 2314
8. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated J Am Geriatr Soc 1986 34 722 727
9. Simpson GM Angus JW. A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 1970 212 11 19
10. Barnes TR. A rating scale for drug-induced akathisia Br J Psychiatry 1989 154 672 676
11. Munetz MR Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale Hosp Community Psychiatry 1988 39 1172 1177
12. Chouinard G Ross-Chouinard A Annable L et al Extrapyramidal Symptom Rating Scale Can J Neurol Sci 1980 7 233
13. Brodaty H Ames D Snowdon J et al A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia J Clin Psychiatry 2003 64 134 143
14. Katz IR Jeste DV Mintzer JE et al Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia A randomized, double-blind trial J Clin Psychiatry 1999 60 107 115
15. De Deyn PP Carrasco MM Deberdt W et al Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease Int J Geriatr Psychiatry 2004 19 115 126
16. Street JS Clark WS Gannon KS et al Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities A double-blind, randomized, placebo-controlled trial Arch Gen Psychiatry 2000 57 968 976
17. Zhong X Sweitzer D Potter L et al A Comparison of the Efficacy and Safety of Quetiapine and Risperidone (Poster) 156th American Psychiatric Association Annual Meeting, May 17-22, 2003, San Francisco, CA.
18. Chan WC Lam LC Choy CN et al A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients Int J Geriatr Psychiatry 2001 16 1156 1162
19. De Deyn PP Rabheru K Rasmussen A et al A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia Neurology 1999 53 946 955
20. Suh G Son HG Ju Y et al A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances Am J Geriatr Psychiatry 2004 12 509 516
21. Tariot P Schneider LS Katz I et al Quetiapine in Nursing Home Residents with Alzheimer's Dementia and Psychosis (Poster). Annual Meeting of the American Association of Geriatric Psychiatry, February 24-27, 2002, Orlando, FL.
22. Fontaine CS Hynan LS Koch K et al A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities J Clin Psychiatry 2003 64 726 730
23. Ellingrod VL Schultz SK Ekstam-Smith K et al Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis Pharmacotherapy 2002 22 1 5
24. Aripiprazole. Clinical Study Report CN138005 [on-line]. Available at Accessed August 12, 2005.
25. Herrmann N Mandani M Lanctot K. Atypical antipsychotics and risk of cerebrovascular accidents Am J Psychiatry 2004 161 1113 1115
26. Liperoti R Gambassi G Lapane KL et al Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest Arch Intern Med 2005 165 696 701
27. Frank L Kleinman L Ciesla G et al The effect of risperidone on nursing burden associated with caring for patients with dementia J Am Geriatr Soc 2004 52 1449 1455
28. Dear Healthcare Professional. Health Canada Health Products and Food Branch [on-line]. Available at Accessed July 27, 2004.
29. Schneider LS Ismail MS Dagerman K et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial Schizophr Bull 2003 29 57 72